JP4716497B2 - External preparation for skin and hyaluronidase inhibitor - Google Patents

Description

  The present invention relates to an external preparation for skin having a hyaluronidase inhibitory action in humans. More specifically, the present invention relates to a skin external preparation that has a hyaluronidase inhibitory action, maintains skin elasticity and elasticity, prevents wrinkles, wrinkles, and roughness, and maintains a moist and youthful skin state.

  In recent years, research on aging has been promoted. As for the cause of skin aging, aging is an important factor when viewed macroscopically, but in addition to that, the effects of drying, oxidation, sunlight (ultraviolet rays) and the like are also directly related to skin aging. As specific phenomena of skin aging, reduction of mucopolysaccharides such as hyaluronic acid, cross-linking reaction of collagen, cell damage due to ultraviolet rays, and the like are known.

Among them, a linear macromolecular polysaccharide in which β-D-N-acetylglucosamine and β-D-glucuronic acid are alternately bound, and chondroitin sulfate and the like are widely present in mammalian connective tissues. Hyaluronic acid is a kind of hyaluronic acid that retains moisture in the cell gap, retains cells based on the formation of a jelly-like matrix in the tissue, retains tissue lubricity and flexibility, and resists external forces such as mechanical failure. And many functions such as prevention of bacterial infection (see Non-Patent Document 1). In addition, it is said that the amount of hyaluronic acid in the skin decreases with aging, and along with this, skin aging such as fine lines and roughness appears. For this reason, many cosmetics containing hyaluronic acid have been proposed as an ameliorating agent for such aging skin. However, these conventional cosmetics only exhibit a moisturizing effect on the skin surface, and cannot essentially improve aging skin. In addition, many cosmetics that have paid out a drug that increases the amount of hyaluronic acid in the skin have recently been proposed (see Patent Document 1), but these also clearly improve and treat aging skin. The current situation has not yet been reached. The reason why the aging skin cannot be clearly improved by the external use of hyaluronic acid or the hyaluronic acid production promoter is considered to be because the degradation rate of hyaluronic acid in the skin is high. It has been reported that hyaluronic acid in the skin is rapidly synthesized because it is synthesized in vivo and simultaneously undergoes enzymatic degradation by its degrading enzyme, hyaluronidase, and the half-life of hyaluronic acid in the skin is about one day. (See Non-Patent Document 2).
Hyaluronidase is an enzyme that is widely distributed in the living body and is also present in the skin. As its name suggests, it degrades hyaluronic acid. Therefore, suppressing the activity of hyaluronidase that promotes the degradation of hyaluronic acid is effective for the stability of hyaluronic acid used in the formulation, the hyaluronic acid in the formulation after application to the skin, and the hyaluronic acid present in the skin. It is thought to contribute to stability. Hyaluronidase is also known as an inflammatory enzyme, and suppressing this activity is known to suppress inflammation and to suppress allergies.
For the above reasons, it is an effective inhibitor of hyaluronidase, a hyaluronic acid-degrading enzyme, to maintain skin elasticity and elasticity, prevent small wrinkles and skin roughness, and maintain a moist and youthful skin condition. Has been sought to develop.

Japanese Patent Laid-Open No. 11-209261 "Bio Industry", vol.8, p.346 (1991) Tammi R. et al ,. J. Invest. Dermatol., 97, 126-130 (1991)

  This invention is made | formed in view of the said situation, and it aims at providing the skin external preparation and the hyaluronidase inhibitor which have the hyaluronidase inhibitory action in humans which can be used safely and easily.

  As a result of investigating the hyaluronidase inhibitory action of a wide variety of substances to solve the above problems, the present inventors have found that a specific plant or extract thereof that has not been known so far has an excellent hyaluronidase inhibitory action. Based on this, the present invention has been completed.

  The present invention relates to Colospermum religiosum (L.) Alston, Clitoria macrophylla, Mesa Macrophylla Wal. (Maesa macrophylla Wall.), Castanopsis indica (Rox.) Miff. (Castanopsis indica (Roxb.) Mif.), Cotonaster Acuminata Lindle. It comprises one or more kinds of plants selected from (Cotoneaster acuminata Lindl.) Or an extract thereof, and an external preparation for skin, and one or more kinds of plants selected from the above or an extract thereof. It is a hyaluronidase inhibitor characterized by this.

The hyaluronidase inhibitor of the present invention has an excellent hyaluronidase inhibitory action, and can be effectively applied to prevent aging of human skin (skin elasticity and elasticity retention).
The topical skin preparation (including pharmaceuticals, quasi-drugs, and cosmetics) containing the hyaluronidase inhibitor of the present invention suppresses the degradation of hyaluronic acid, which is one of the extracellular matrix components, and improves skin elasticity and elasticity. Holds and prevents wrinkles, wrinkles, and bulkiness, and maintains a moist and youthful skin condition.

Hereinafter, the present invention will be described in detail.
Cochlospermum religiosum (L.) Alston, which is used in the present invention, is a plant belonging to the family Aceraceae, a deciduous shrub, and the leaves are split into five palms. The flowers bloom in the deciduous period and are beautiful with bright yellow and large flowers attached to the conical inflorescences at the tops of the branches. In addition to being cultivated for ornamental purposes, amber resin (gum) is collected. Bark decoction is used to treat cough, diarrhea and dysentery.

  Clitoria macrophylla used in the present invention is a leguminous butterfly genus plant, is a dicotyledonous plant, and is a climbing herb or shrub. Distributed in temperate and warm regions. Useful for the treatment of tuberculosis, liver damage and rash.

  Maesa macrophylla Wall. Used in the present invention is a dicotyledonous plant, a dicotyledonous plant, and is an evergreen shrub or a high tree. Distributed from Africa and India to the temperate regions of East Asia, Malaysia and Australia. The decoction juice of young leaves with flowers is considered to be an anthelmintic agent, and the extracts of leaves and flowers show an insecticidal effect.

  Castanopsis indica (Roxb.) Mif. Used in the present invention is a plant belonging to the genus Beechidae, and is an evergreen tree, sometimes forming a pure forest. Distributed from the Himalayas to Southeast Asia and the southern part of mainland China, the fruits are edible. The material is hard and is used in the manufacture of building materials, furniture and utensils. The bark and leaves contain tannin, exhibit antitumor and antiviral effects, and are used for tanning. Leaf paste is used for headaches.

  Cotoneaster acuminata Lindl. Used in the present invention is a plant belonging to the genus Rosaceae (Cotoneaster), which is a dicotyledonous plant and is a shrub, sometimes a small tree. There are evergreen and deciduous ones, and white and reddish flowers range from cups to flat ones. Fruits range from red ripening to black ripening and vary from spherical to elliptical. Many species, more than 40 species, from the Himalayas to China have been described and are distributed from Central Asia to Europe. Useful when constipation or cardiac function declines.

  In the present invention, the plant can be used raw or dried, but is preferably used as a dry powder or an extract from the viewpoints of usability and formulation.

  Although the whole plant body can be used as the site of use of the plant of the present invention, seeds, fruits, flowers, leaves, stems, bark or xylem are preferably used. The “flower” in this case refers to those containing various organs involved in sexual reproduction, including so-called flower axes and flower leaves, and includes petals, stamens, pistils, sepals, and the like.

Cochlospermum religiosum (L.) Alston used in the present invention preferably uses bark, but other sites can also be used.
Clitoria macrophylla used in the present invention is preferably whole plant, but other parts can also be used.
Maesa macrophylla Wall. Used in the present invention preferably uses young leaves with flowers, but other sites can also be used.
Castanopsis indica (Roxb.) Mif. Used in the present invention is preferably leaves, particularly young leaves, but other sites can also be used.
Cotoneaster acuminata Lindl. Used in the present invention preferably uses flowers, but other parts can also be used.

  The plant extract of the present invention can be obtained by a conventional method. For example, the plant extract can be obtained by immersing or heating and refluxing a plant with an extraction solvent, followed by filtration and concentration. As the extraction solvent, any solvent that is usually used for extraction can be used. For example, water, methanol, ethanol, propylene glycol, 1,3-butylene glycol, glycerin and other alcohols, hydrous alcohols, chloroform , Organic solvents such as dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane and the like can be used alone or in combination. The extract obtained by extraction with the above solvent is adsorbed as it is, or the concentrated extract is adsorbed by an adsorption method, for example, by removing impurities using an ion exchange resin, or by a column of a porous polymer (eg Amberlite XAD-2). Thereafter, a product eluted with methanol or ethanol and concentrated can also be used. Further, a partitioning method, for example, an extract extracted with water / ethyl acetate can be used.

  All of the above plants or extracts thereof thus obtained have an excellent hyaluronidase inhibitory action. Such a plant or an extract thereof is preferably used by blending with a skin external preparation.

  When the above-mentioned plant or extract thereof is blended and used in a skin external preparation, it is preferably blended in the total amount of the external preparation in a dry weight of 0.0005 to 20% by mass, more preferably 0.001 to 10% by mass. . If it is less than 0.0005% by mass, the hyaluronidase inhibitory effect of the present invention is not sufficiently exerted. Moreover, even if it mixes exceeding 10 mass%, the improvement of the big effect is not recognized.

  In addition to the above components, the external preparation for skin of the present invention is a component that is usually used for external preparations for skin such as cosmetics and pharmaceuticals, for example, a moisturizing agent and an antioxidant, as long as the effects of the present invention are not impaired. Oils, UV protection agents, surfactants, thickeners, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, and the like can be appropriately blended as necessary.

  Furthermore, edetate disodium, edetate trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, preservatives such as methylparaben, ethylparaben, butylparaben, caffeine, tannin, Verapamil, tranexamic acid and its derivatives, licorice extract, grabrizine, hot water extract of karin fruit, various herbal medicines, tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, Whitening agents such as ascorbic acid glucoside, arbutin and kojic acid, sugars such as glucose, fructose, mannose, sucrose and trehalose, vitamin A derivatives such as retinoic acid, retinol, retinol acetic acid and notinol palmitic acid It may be blended Domo.

  Further, the external preparation for skin of the present invention can be widely applied to cosmetics, quasi-drugs, etc., particularly preferably cosmetics applied to the outer skin, and the dosage form can also be applied to the skin. Any agent may be used as long as it is a solution, solubilization system, emulsification system, powder dispersion system, water-oil two-layer system, water-oil-powder three-layer system, ointment, lotion, gel, aerosol, etc. The type is applied.

  The use form of the external preparation for skin of the present invention is also arbitrary. For example, facial cosmetics such as lotions, emulsions, creams and packs, makeup cosmetics such as foundations, lipsticks and eye shadows, aromatic cosmetics, and hair cosmetics. It can be used for a coating material, a bath agent and the like.

  In addition, the form which the skin external preparation of this invention can take is not limited to said dosage form and usage form.

In addition, the hyaluronidase inhibitor of the present invention is a topical agent for inhibiting hyaluronic acid degradation that acts directly on cells derived from human connective tissue to inhibit hyaluronic acid degradation, and prevents skin aging such as fine wrinkles and roughness due to a decrease in the amount of hyaluronic acid In addition to cosmetics to prevent aging, foods that prevent a decrease in the amount of hyaluronic acid in the human body, symptoms of abnormally increased hyaluronic acid degradation, especially gingivitis, rheumatism and osteoarthritis, arthritis prevention treatment, initial treatment of burns It can be applied to a pharmaceutical composition such as a therapeutic agent for abnormal degradation of hyaluronic acid for the above.
When the hyaluronidase inhibitor of the present invention is administered to the human body as a drug, it is usually taken orally so that the daily dose is 100 μg to 10 g, preferably about 10 mg to 1 g. The dosage form is arbitrarily used as a powder, tablet, capsule or the like.
When the hyaluronidase inhibitor of the present invention is used as a pharmaceutical composition, the dosage form is not particularly limited and can be appropriately selected depending on the administration route and the like. For example, tablets, capsules, powders, fine granules, granules, solutions, syrups and the like can be mentioned as preparations suitable for oral administration, and injections, drops, Suppositories, inhalants, transdermal absorbents, transmucosal absorbents, patches and the like can be mentioned. The injection may be used for any of intravenous injection, intramuscular injection, subcutaneous injection, infusion and the like.

  EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, the technical scope of this invention is not limited at all by this. In addition, all compounding quantities are the mass%.

Prior to the examples, the test method for the hyaluronidase inhibitory action of the plant-derived extract of the present invention will be described.
1. Preparation of sample (plant extract) (Production Example 1)
200 mL of methanol was added to 10.0 g of bark of Cochlospermum religiosum (L.) Alston, immersed for 7 days at room temperature, and then filtered. The methanol in the filtrate was distilled off to obtain 1.604 g (in terms of dry matter) of the extract.

(Production Example 2)
200 mL of methanol was added to 20.1 g of whole plant of Clitoria macrophylla, and after immersion at room temperature for 7 days, it was filtered. The methanol in the filtrate was distilled off to obtain 1.154 g (converted to dry matter) of the extract.

(Production Example 3)
100 mL of methanol was added to 10.07 g of young leaves with flowers of Maesa macrophylla Wall., And the mixture was immersed for 7 days at room temperature and then filtered. The methanol in the filtrate was distilled off to obtain 1.106 g of extract (in terms of dry matter).

(Production Example 4)
100 mL of methanol was added to 9.9 g of leaves (young leaves) of Castanopsis indica (Roxb.) Mif., And immersed for 7 days at room temperature, followed by filtration. The methanol in the filtrate was distilled off to obtain 0.588 g (in terms of dry matter) of the extract.

(Production Example 5)
100 mL of methanol was added to 10.02 g of flowers of Cotoneaster acuminata Lindl., Immersed for 7 days at room temperature, and then filtered. The methanol in the filtrate was distilled off to obtain 1.076 g (in terms of dry matter) of the extract.

  The following experiments were performed using the plant extracts obtained in Production Examples 1 to 5.

2. Hyaluronidase activity inhibition test The inhibitory action was evaluated by determining the hyaluronidase inhibitory activity of plant extracts at final concentrations of 0.05%, 0.1% and 0.5% of each extract.
Specifically, 0.05 ml of a test sample adjusted to a predetermined concentration was added to 0.1 ml of a hyaluronidase solution derived from bovine testicles (Sigma; type 1-S, final concentration 250 units / ml 0.1 M acetate buffer (pH 4.0) ) Was dissolved and incubated at 37 ° C. for 20 minutes. Furthermore, 0.1 ml of activator (Compound 48/80, manufactured by Sigma, dissolved in the above-mentioned acetate buffer so that the final concentrations of CaCl ₂ and NaCl are 0.1 mg / ml, 2.5 mM and 0.15 M, respectively. ) Was added and incubated at 37 ° C. for 20 minutes. To this was added 0.25 ml of a sodium hyaluronate (Nacalai Tesque microorganisms) solution and incubated at 37 ° C. for 40 minutes, and then 0.1 ml of 0.4N NaOH was added to stop the reaction. After cooling with ice for 10 minutes, 0.1 ml of borate buffer (pH 9.0) was added, boiled for 3 minutes, then ice-cooled again for 10 minutes, then 3 ml of p-dimethylaminobenzaldehyde reagent was added, and the mixture was incubated at 37 ° C. for 20 minutes. Incubated. Absorbance at 585 nm was measured for the resulting reaction solution, and the inhibition rate was determined by comparison with a blank added with an acetate buffer instead of the sample solution or enzyme solution. The results are shown in Table 1.

  As is apparent from Table 1, the plant extract according to the present invention has an excellent hyaluronidase inhibitory effect.

Below, the formulation example of this invention is shown further. In addition, the plant extract used in each formulation example was obtained by a conventional method. The amount of these extracts is shown by dry weight. Here, Examples 2, 7, 15, and 20 are reference examples not included in the present invention.

Example 1 Cream (formulation component) (mass%)
(1) Stearic acid 2.0
(2) Stearyl alcohol 7.0
(3) Hydrogenated lanolin 2.0
(4) Squalane 5.0
(5) 2-Octyldodecyl alcohol 6.0
(6) Polyoxyethylene (25 mol)
Cetyl alcohol ether 3.0
(7) Glycerin monostearate ester 2.0
(8) Propylene glycol 5.0
(9) Cochlospermum religiosum (L.) Alston methanol extract 0.05
(10) Sodium bisulfite 0.03
(11) Ethylparaben 0.3
(12) Perfume appropriate amount (13) Purified water Residue (Production method)
(8) was added to (13) and dissolved, and heated to 70 ° C. (water phase). On the other hand, (1) to (7) and (9) to (12) were mixed, heated and melted, and kept at 70 ° C. (oil phase). Subsequently, the oil phase was added to the aqueous phase, preliminarily emulsified, and uniformly emulsified with a homomixer, and then cooled to 30 ° C. with good stirring.

Example 2 Cream (formulation component) (mass%)
(1) Solid paraffin 5.0
(2) Beeswax 10.0
(3) Vaseline 15.0
(4) Glycerin monostearate ester 2.0
(5) Polyoxyethylene (20 mol)
Sorbitan monolaurate 3.0
(6) Soap powder 0.1
(7) Borax 0.2
(8) Acetone extract of Clitoria macrophylla 0.05
(9) Ethanol extract of Clitoria macrophylla 0.05
(10) Sodium bisulfite 0.03
(11) Ethylparaben 0.3
(12) Perfume appropriate amount (13) Purified water Residue (Production method)
(6) to (7) were added to (13), dissolved by heating and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (5) and (8) to (12) were mixed, heated and melted, and kept at 70 ° C. (oil phase). Next, the oil phase was gradually added to the aqueous phase while stirring to carry out the reaction. After completion of the reaction, the mixture was uniformly emulsified with a homomixer and then cooled to 30 ° C. with good stirring.

Example 3 Emulsion (formulation component) (mass%)
(1) Stearic acid 2.5
(2) Cetyl alcohol 1.5
(3) Vaseline 5.0
(4) Liquid paraffin 10.0
(5) Polyoxyethylene (10 mol)
Monooleate 3.0
(6) Polyethylene glycol 1500 3.0
(7) Triethanolamine 1.0
(8) Carboxyvinyl polymer 0.05
(9) Maesa macrophylla Wall. Ethyl acetate extract 0.05
(10) Sodium bisulfite 0.01
(11) Ethylparaben 0.01
(12) Perfume appropriate amount (13) Purified water Residue (Production method)
(8) was dissolved in a small amount of (13) (A phase). (6) to (7) were added to the remaining (13), dissolved by heating and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (5) and (9) to (12) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase for preliminary emulsification, and the A phase was further added and uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. with good stirring.

Example 4 Emulsion (formulation component) (mass%)
(1) Microcrystalline wax 1.0
(2) Beeswax 2.0
(3) Lanolin 20.0
(4) Liquid paraffin 10.0
(5) Squalane 5.0
(6) Sorbitan sesquioleate ester 4.0
(7) Polyoxyethylene (20 mol)
Sorbitan monooleate 1.0
(8) Propylene glycol 7.0
(9) Acetone extract of Castanopsis indica (Roxb.) Mif. 10.0
(10) Sodium bisulfite 0.01
(11) Ethylparaben 0.3
(12) Perfume appropriate amount (13) Purified water Residue (Production method)
(8) was added to (13) and heated to 70 ° C. (aqueous phase). On the other hand, (1) to (7) and (9) to (12) were mixed, melted by heating and kept at 70 ° C. (oil phase). The aqueous phase was gradually added while stirring the oil phase, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. with good stirring.

Example 5 Jelly (blending component) (mass%)
(1) 95% ethyl alcohol 10.0
(2) Dipropylene glycol 15.0
(3) Polyoxyethylene (50 mol)
Oleyl alcohol ether 2.0
(4) Carboxyvinyl polymer 1.0
(5) Caustic soda 0.15
(6) L-arginine 0.1
(7) 50% 1,3-butylene glycol extract of Cotoneaster acuminata Lindl. 7.0
(8) 2-hydroxy-4-methoxy
Sodium benzophenone sulfonate 0.05
(9) Ethylenediaminetetraacetate
Trisodium dihydrate 0.05
(10) Methylparaben 0.2
(11) Perfume appropriate amount (12) Purified water Residue (Production method)
(4) was uniformly dissolved in (12) (aqueous phase). On the other hand, (7) and (3) were dissolved in (1) and added to the aqueous phase. Next, (2) and (8) to (11) were added thereto, and then neutralized and thickened with (5) and (6).

Example 6 Cosmetic liquid (formulation component) (mass%)
(Phase A)
(1) 95% ethyl alcohol 10.0
(2) Polyoxyethylene (20 mol) octyldodecanol 1.0
(3) Pantothenyl ethyl ether 0.1
(4) Cochlospermum religiosum (L.) Alston methanol extract 1.5
(5) Methylparaben 0.15
(Phase B)
(6) Potassium hydroxide 0.1
(Phase C)
(7) Glycerin 5.0
(8) Dipropylene glycol 10.0
(9) Sodium bisulfite 0.03
(10) Carboxyvinyl polymer 0.2
(11) Purified water residue (production method)
The A phase and the C phase were uniformly dissolved, and the A phase was added to the C phase and solubilized. Then phase B was added and filled.

Example 7 Pack (blending ingredients) (mass%)
(Phase A)
(1) Dipropylene glycol 5.0
(2) Polyoxyethylene (60 mol) hydrogenated castor oil 5.0
(Phase B)
(3) Methanol extract of Clitoria macrophylla 0.01
(4) Olive oil 5.0
(5) Tocopherol acetate 0.2
(6) Ethylparaben 0.2
(7) Fragrance 0.2
(Phase C)
(8) Sodium bisulfite 0.03
(9) Polyvinyl alcohol (degree of saponification 90, degree of polymerization 2000) 13.0
(10) Ethanol 7.0
(11) Purified water residue (production method)
A phase, B phase, and C phase were uniformly dissolved, and B phase was added to A phase to solubilize. C phase was then added and filled.

Example 8 Solid foundation (blending component) (mass%)
(1) Talc 43.1
(2) Kaolin 15.0
(3) Sericite 10.0
(4) Zinc flower 7.0
(5) Titanium dioxide 3.8
(6) Yellow iron oxide 2.9
(7) Black iron oxide 0.2
(8) Squalane 8.0
(9) Isostearic acid 4.0
(10) POE sorbitan monooleate 3.0
(11) Isocetyl octanoate 2.0
(12) Ethanol extract of Maesa macrophylla Wall. 1.0
(13) Preservative appropriate amount (14) Fragrance appropriate amount (production method)
(1)-(7) powder components are sufficiently mixed with a blender, (8)-(11) oily components, (12), (13), (14) are added to this and kneaded well. Filled and molded.

Example 9 Emulsification foundation (cream type)
(Compounding ingredients)
(Powder part)
(1) Titanium dioxide 10.3
(2) Celiteite 5.4
(3) Kaolin 3.0
(4) Yellow iron oxide 0.8
(5) Bengala 0.3
(6) Black iron oxide 0.2
(Oil phase)
(7) Decamethylcyclopentasiloxane 11.5
(8) Liquid paraffin 4.5
(9) Polyoxyethylene-modified dimethylpolysiloxane 4.0
(Water phase)
(10) Purified water 50.0
(11) 1,3-butylene glycol 4.5
(12) Castanopsis indica (Roxb.) Mif. 30% 1,3-butylene glycol extract 1.5
(13) Preservative appropriate amount (14) Fragrance appropriate amount (production method)
After the aqueous phase was heated and stirred, the powder part sufficiently mixed and ground was added and homomixed. Furthermore, after adding the heat-mixed oil phase and carrying out a homomixer process, the fragrance | flavor was added while stirring and it cooled to room temperature.

Example 10 Cream (Compounding ingredient) (mass%)
(1) Stearic acid 2.0
(2) Stearyl alcohol 7.0
(3) Hydrogenated lanolin 2.0
(4) Squalane 5.0
(5) 2-Octyldodecyl alcohol 6.0
(6) Polyoxyethylene (25 mol)
Cetyl alcohol ether 3.0
(7) Glycerin monostearate ester 2.0
(8) Propylene glycol 5.0
(9) Cotoneaster acuminata Lindl. Methanol extract 0.05
(10) Sodium bisulfite 0.03
(11) Ethylparaben 0.3
(12) Perfume appropriate amount (13) Purified water Residue (Production method)
(8) was added to (13) and dissolved, and heated to 70 ° C. (water phase). On the other hand, (1) to (7) and (9) to (12) were mixed, dissolved by heating, and kept at 70 ° C. (oil phase). Subsequently, the oil phase was added to the aqueous phase, preliminarily emulsified, and uniformly emulsified with a homomixer, and then cooled to 30 ° C. with good stirring.

Example 11 Toner lotion (blending component) (mass%)
(1) Ethanol 5.0
(2) Glycerin 0.5
(3) Dipropylene glycol 2.0
(4) 1,3-butylene glycol 6.0
(5) Citric acid 0.02
(6) Sodium citrate 0.08
(7) Sodium hexametaphosphate 0.03
(8) Hydroxypropyl-β-cyclodextrin 0.1
(9) Cochlospermum religiosum (L.) Alston
50% 1,3 butylene glycol extract (solids concentration 1.0%) 0.3
(10) Ethanol extract of Clitoria macrophylla 0.1
(11) 50% ethanol extract of Maesa macrophylla Wall. 0.1
(12) Lavender oil 0.1
(13) Sodium alginate 0.001
(14) Purified water residue (production method)
(1) to (14) were mixed and dissolved according to a conventional method to obtain a skin lotion.

Example 12 Emulsion (formulation component) (mass%)
(1) Dimethylpolysiloxane 3.0
(2) Decamethylcyclopentasiloxane 4.0
(3) Ethanol 5.0
(4) Glycerin 6.0
(5) 1,3-butylene glycol 5.0
(6) Polyoxyethylene methyl glucoside 3.0
(7) Squalane 2.0
(8) Potassium hydroxide 0.1
(9) Sodium hexametaphosphate 0.05
(10) Castanopsis indica (Roxb.) Mif.
30% 1,3-butylene glycol extract (solid concentration 1.5%) 0.3
(11) Xanthan gum 0.3
(12) Carboxyvinyl polymer 0.1
(13) Acrylic acid / alkyl methacrylate copolymer 0.1
(14) Methyl paraben appropriate amount (15) Fragrance appropriate amount (16) Purified water Residue (Production method)
(9), (12) and (13) were added to (16) and dissolved, and further mixed with (10) and (4) to (6). Here, (14), (11) and (15) are added to and dissolved in (3) and mixed, and the mixture of (1), (2) and (7) is added to emulsify, It was neutralized and thickened by (8).

Example 13 Emulsion (formulation component) (mass%)
(1) Vaseline 1.0
(2) Dimethylpolysiloxane 3.0
(3) Methylphenylpolysiloxane 3.0
(4) Stearyl alcohol 0.5
(5) Glycerin 7.0
(6) Dipropylene glycol 3.0
(7) 1,3-butylene glycol 7.0
(8) Squalane 1.0
(9) Isostearic acid 0.5
(10) Stearic acid 0.5
(11) Polystearic acid polyoxyethylene glycerol 1.0
(12) Glycerol monostearate 2.0
(13) Potassium hydroxide 0.05
(14) Cotoneaster acuminata Lindl. Methanol extract 0.1
(15) EDTA trisodium 0.05
(16) Carboxyvinyl polymer 0.1
(17) Phenoxyethanol appropriate amount (18) perfume appropriate amount (19) purified water residue (production method)
(6), (7), (13) was added to (19) and heated to maintain at 70 ° C. (aqueous phase). On the other hand, (1) to (4), (8) to (12) and (17) were mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added while stirring the aqueous phase, and (15), (16), (18), (5) and (14) are further added, and the mixture is uniformly emulsified with a homomixer. Cooled to 30 ° C.

  Each of the external preparations for skin of Examples 1 to 13 is excellent in hyaluronidase inhibitory effect. By applying this to the skin, the skin's elasticity and elasticity are maintained, and the skin is moist and youthful. Can be maintained.

Examples 14 to 16 (Liquid)
A syrup was prepared by the method described later with the formulation shown in Table 2 below.
(Manufacturing method)
Each component was dissolved in purified water, stirred and homogenized to obtain a syrup.

Examples 17 to 19 (joint injection)
A joint injection was prepared by the method described later with the formulation shown in Table 3 below.
(Manufacturing method)
An aqueous solution of the components shown in Table 3 was heated or sterilized by filtration, and dispensed in an amount of 2.5 ml into an injection syringe to prepare a joint injection.

Example 20 (troche)
A troche was produced by the conventional method with the following formulation.
Gum arabic 6.0% by mass
Glucose 73.0
Clitoria macrophylla extract 0.05
Potassium phosphate 0.2
Potassium phosphate 0.1
Lactose 17.0
Fragrance 0.1
Magnesium stearate

Examples 21 to 22 (tablets)
Tablets were prepared with the compositions shown in Table 4 below.

(Manufacturing method)
The above ingredients were mixed uniformly and tableted to give 170 mg of 1 tablet according to a conventional method.

Example 23 (Liquid)
A liquid preparation was prepared with the composition shown in Table 5 below.

(Manufacturing method)
Each component described above was dissolved in purified water, and the mixture was stirred and homogenized to obtain a liquid agent.

Example 24 (injection)
The plant extract prepared above, sodium chloride and benzyl alcohol were dissolved in distilled water in the amounts shown in Table 6 below. The solution was filtered through a filter (pore size 0.2 μm) to produce an injection.

Example 25 (functional black tea)
Commercial tea leaves were crushed and the plant extracts prepared above (Cochlospermum religiosum (L.) Alston, Clitoria macrophylla, Maesa macrophylla Wall., Castanopsis indica (Roxb.) Mif., Cotoneaster acuminata Lindl.) The mixture was added to 0.1% by mass, mixed well, and packed in a tea pack. By putting this tea pack in hot water, it was possible to prepare a functional black tea in which the prepared compound was eluted in black tea.

Claims (2)

Skin characterized by blending one or more plants selected from Cochlospermum religiosum (L.) Alston , Maesa macrophylla Wall., Castanopsis indica (Roxb.) Mif., Cotoneaster acuminata Lindl. Topical agent. Hyaluronidase inhibition characterized by comprising one or more plants selected from Cochlospermum religiosum (L.) Alston , Maesa macrophylla Wall., Castanopsis indica (Roxb.) Mif., Cotoneaster acuminata Lindl. Agent.